Summary
Pfizer reported strong second-quarter earnings, driven by Eliquis and new acquisitions, and announced plans for $2.5 billion in cost savings by 2029. The company aims to shift focus to innovative treatments and expects significant growth post-2028, including advancements in obesity treatment.